Titre :

Changes in mental health symptoms from pre-covid-19 to covid-19 among participants with systemic sclerosis from four countries: a scleroderma patient-centered intervention network (spin) cohort study

Auteur(s) :

Thombs, Brett D. [Auteur]
Kwakkenbos, Linda [Auteur]
Henry, Richard S. [Auteur]
Carrier, Marie-Eve [Auteur]
Patten, Scott [Auteur]
Harb, Sami [Auteur]
Bourgeault, Angelica [Auteur]
Tao, Lydia [Auteur]
Bartlett, Susan J. [Auteur]
Mouthon, Luc [Auteur]
Varga, John [Auteur]
Benedetti, Andrea [Auteur]

Titre de la revue :

Journal of Psychosomatic Research

Nom court de la revue :

J Psychosom Res

Numéro :

139

Pagination :

110262

Date de publication :

2020-10-03

ISSN :

1879-1360

Mot(s)-clé(s) :

Pandemic
Epidemiology
Depressive symptoms
Scleroderma
Systemic sclerosis
Adult
Anxiety
Clinical epidemiology
COVID-19
Depressed mood

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

No studies have reported mental health symptom comparisons prior to and during COVID-19 in vulnerable medical populations. To compare anxiety and depression symptoms among people with a pre-existing medical condition and ...
Lire la suite >No studies have reported mental health symptom comparisons prior to and during COVID-19 in vulnerable medical populations. To compare anxiety and depression symptoms among people with a pre-existing medical condition and factors associated with changes. Pre-COVID-19 Scleroderma Patient-centered Intervention Network Cohort data were linked to COVID-19 data from April 2020. Multiple linear and logistic regression were used to assess factors associated with continuous change and ≥ 1 minimal clinically important difference (MCID) change for anxiety (PROMIS Anxiety 4a v1.0; MCID = 4.0) and depression (Patient Health Questionnaire-8; MCID = 3.0) symptoms, controlling for pre-COVID-19 levels. Mean anxiety symptoms increased 4.9 points (95% confidence interval [CI] 4.0 to 5.7). Depression symptom change was negligible (0.3 points; 95% CI -0.7 to 0.2). Compared to France (N = 159), adjusted anxiety symptom change scores were significantly higher in the United Kingdom (N = 50; 3.3 points, 95% CI 0.9 to 5.6), United States (N = 128; 2.5 points, 95% CI 0.7 to 4.2), and Canada (N = 98; 1.9 points, 95% CI 0.1 to 3.8). Odds of ≥1 MCID increase were 2.6 for the United Kingdom (95% CI 1.2 to 5.7) but not significant for the United States (1.6, 95% CI 0.9 to 2.9) or Canada (1.4, 95% CI 0.7 to 2.5). Older age and adequate financial resources were associated with less continuous anxiety increase. Employment and shorter time since diagnosis were associated with lower odds of a ≥ 1 MCID increase. Anxiety symptoms, but not depression symptoms, increased dramatically during COVID-19 among people with a pre-existing medical condition.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2021-07-06T12:48:43Z